MSB 0.38% $1.32 mesoblast limited

Ann: P3 Trial of MSB's Cell Therapy in CHF Completes Recruitment, page-29

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 19,420 Posts.
    lightbulb Created with Sketch. 6515
    The LVAD results were quite encouraging for CHF trial if you looked at it carefully, but I do think CHF is the most high risk of all the MSB trials.

    Rather than a total failure (unlikely after the interim results), the biggest risk is that the benefit is minor and below the threshold at which insurance companies will pay for the treatment. It is important to keep in mind that MSB doesn't fail as a company if the CHF trial fails - there is plenty of upside at the current SP just in what we know works.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.32
Change
-0.005(0.38%)
Mkt cap ! $1.478B
Open High Low Value Volume
$1.31 $1.32 $1.28 $977.1K 754.2K

Buyers (Bids)

No. Vol. Price($)
15 7978 $1.31
 

Sellers (Offers)

Price($) Vol. No.
$1.32 15147 5
View Market Depth
Last trade - 12.29pm 01/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.